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Abstract
Avian and human influenza A viruses alike have shown a capacity to use the eye as a portal of 
entry and cause ocular disease in human beings. However, whereas influenza viruses generally 
represent a respiratory pathogen and only occasionally cause ocular complications, the H7 virus 
subtype stands alone in possessing an ocular tropism. Clarifying what confers such non-respiratory 
tropism to a respiratory virus will permit a greater ability to identify, treat, and prevent zoonotic 
human infection following ocular exposure to influenza viruses; especially those within the H7 
subtype, which continue to cause avian epidemics on many continents.
Introduction
There is a great diversity among influenza A viruses associated with human infection. 
Human influenza viruses are responsible for annual epidemics and infrequent pandemics, 
leading to a high burden of disease worldwide each year. Zoonotic influenza viruses have 
repeatedly crossed the species barrier, causing human disease that ranges from subclinical to 
life-threatening.1 Although these influenza viruses generally lack the capacity for sustained 
human-to-human transmission, the absence of pre-existing immunity in human populations 
to these viruses and the ability to cause severe human illness nonetheless underscore their 
pandemic potential. The high infectivity of influenza viruses, and capacity for viruses to 
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remain suspended in the air for sustained distance and duration,2,3 further illustrates the 
constant public health threat posed by this pathogen.
Influenza viruses typically cause respiratory disease in human beings, associated with fever, 
chills, headache, nasal discharge, sore throat, coughing, and sneezing in uncomplicated 
cases.4 However, several non-respiratory clinical features can also occur among infected 
individuals, including ocular (typically mild conjunctivitis) and gastrointestinal (typically 
diarrhoea) depending on the severity of disease and causative strain; complications including 
secondary bacterial pneumonia or (rarely) neurological involvement (including Guillain-
Barré syndrome and encephalitis) are uncommon but documented.4,5 Similarly, respiratory 
exposure is but one of several potential routes of influenza virus infection in human beings. 
Owing to the heterogeneity inherent in the capacity of influenza A viruses to cause illness 
following multiple modes of infection, there is a need for both a greater understanding of 
how non-respiratory exposure routes influence disease presentation and progression in 
mammalian hosts, and heightened investigation regarding the susceptibility of non-
respiratory tissues to both human and avian influenza viruses.
The eye is susceptible to avian and human influenza virus infection
In human beings, influenza virus infections generally follow respiratory exposure and cause 
respiratory symptoms as the primary manifestation of disease. The distribution of influenza 
virus cellular receptors in the human respiratory tract (terminal sialic acids linked to 
galactose via α2,3 or α2,6 glycosidic bonds) is believed to govern host range and tropism, 
with human influenza viruses preferentially binding to α2,6 linked sialic acid, and avian 
influenza viruses preferentially binding to α2,3 linked sialic acid.6 However, the ocular 
surface (notably the corneal and conjunctival epithelia) represents an often overlooked 
mucosal surface that, like the respiratory tract, bears permissive receptors for influenza 
virus, primarily in an α2,3 linkage.7
Thus, a better understanding of viruses or virus subtypes that exhibit a non-respiratory 
tropism will facilitate identification of the properties that confer tissue preference in human 
beings. With the exception of low pathogenic avian influenza (LPAI) and high pathogenic 
avian influenza (HPAI) A H7N9 viruses causing human respiratory infection in east Asia, 
roughly 80% of documented human infections with H7 subtype viruses have been associated 
with ocular complications (often with concurrent mild respiratory disease)8 and an 
influenza-virus positive eye swab (table 1), supporting the ocular tropism of this virus 
subtype. This finding clearly contrasts with other avian and human influenza viruses, which 
have occasionally shown a capacity to cause ocular complications (typically reported as 
conjunctivitis) but do not exhibit a particular affinity towards ocular tissue (table 2). For 
example, conjunctivitis or pink eye was reported in 0·45% and 0·70% of patients admitted to 
hospital of all ages with laboratory-confirmed influenza during the 2014–15 to 2016–17 
seasons, respectively (table 3), a low but still measurable percentage of all virus-confirmed 
patients in this cohort.
It should be noted that most of these reports do not confirm the presence of influenza virus 
by isolation from eyes (typically only tested among possible H7 virus cases), and often do 
Belser et al. Page 2













not rule out the presence of other common bacterial or viral pathogens (such as adenovirus), 
that are known to cause conjunctivitis. As such, these studies demonstrate an association of 
conjunctivitis with respiratory influenza in the absence of confirmation that the ocular 
symptoms are caused by influenza virus infection, and identify a need to collect and 
examine ocular samples (eg, eye swabs) when ocular involvement is reported during 
confirmed infection with a respiratory pathogen. Although these limitations make it difficult 
to ascertain the prevalence of ocular complications among influenza virus-infected 
individuals from these isolated studies, collectively these data nonetheless indicate that 
human beings are susceptible to ocular involvement following infection with a diverse group 
of influenza A viruses.
Conjunctivitis, or inflammation of the conjunctiva and eyelid, is the primary ocular 
complication reported in individuals with confirmed influenza virus infection, but additional 
ocular findings have also been documented, including (but not limited to) subconjunctival 
haemorrhage, uveitis, retinopathy, and optic neuritis.32,38 Most of these reports describe 
previously healthy individuals; further data are needed to determine whether 
immunocompromised individuals are more susceptible to non-respiratory influenza virus 
exposure or are more likely to present with ocular complications following influenza virus 
infection. In the absence of antiviral treatments that specifically target ocular disease caused 
by RNA viruses,7 influenza-positive patients presenting with conjunctivitis or other ocular 
complications are typically treated with oseltamivir (table 1).32
Although there are several isolated reports of ocular involvement following infection with 
avian and human influenza A viruses (tables 1, 2), there is a need for increased consistency 
in reporting the absence or presence of ocular complications in individuals with confirmed 
influenza virus infection, especially for individuals whose infection might be associated with 
occupational exposure. Studies have shown reduced viral loads in individuals exposed to live 
attenuated influenza vaccine wearing both ocular and respiratory protection compared with 
respiratory protection alone,39 indicating a crucial role for eye protection. However, robust 
data regarding eye protection compliance (concurrent with use of respiratory protection) 
among individuals with potential occupational exposure to influenza virus is often lacking or 
not documented. Furthermore, potential ocular exposure (ie, by infectious aerosols, fomites, 
or virus-containing liquids) to influenza virus is not frequently reported in retrospective 
epidemiological studies among non-H7 subtype viruses, despite the capacity for many 
influenza viruses to use the eye to cause a respiratory infection. H7 subtype viruses in cases 
presenting with conjunctivitis have been confirmed in either respiratory samples or eye 
swabs, although eye swabs are more frequently positive than throat swabs (by either RT-
PCR or virus culture), with most cases detected within the first 4–5 days after illness onset.
15,16 In support of antiviral treatment of influenza virus-associated conjunctivitis (table 1), 
efficacy of the neuraminidase inhibitor oseltamivir following ocular inoculation of mice or 
ferrets with influenza viruses has been shown to reduce viral replication and limit virus 
transmissibility,40,41 but further study is needed regarding the bioavailability of oseltamivir 
to the eye and use of antiviral agents when conjunctivitis is the primary manifestation of 
PCR-confirmed influenza and co-infection with other potential pathogens has been ruled 
out.
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Ocular tropism can be measured in the laboratory
The study of small mammalian models has greatly improved our understanding of influenza 
viruses to infect and cause disease by the ocular route. Ocular inoculation of ferrets using 
either a liquid or aerosol inoculum has identified that both human and avian influenza 
viruses can cause a productive, transmissible respiratory infection following this exposure 
route (table 4). Interestingly, these studies have revealed reduced clinical signs of infection, 
less efficient virus transmission, and diminished induction of innate host responses 
following ocular compared with respiratory inoculation.43,44 As supported by studies in 
human beings,39 replication-independent drainage of inoculum from the ocular surface to 
the nasal mucosa and respiratory tract via the nasolacrimal duct has been shown in the ferret 
model.43 Although these ferret studies have underscored the capacity for both avian and 
human influenza viruses to cause respiratory disease following ocular-only exposure, this 
species does not reflect the apparent ocular tropism associated with H7 virus infection; 
further immunohistochemical or histopathological studies are warranted to more closely 
examine this finding. By contrast, mice inoculated by the ocular route with H7 subtype 
viruses possess detectable virus in ocular and respiratory tissues with increased frequency 
postinoculation compared with A H5N1 or seasonal influenza viruses.45,46
Similar to other principal respiratory viruses such as adenovirus and respiratory syncytial 
virus, numerous ocular cell types support productive replication of both avian and human 
influenza viruses in vitro.47–51 These studies have largely examined the capacity for 
influenza virus replication in cultured human ocular (corneal or conjunctival) epithelial cells 
or human conjunctival organ cultures, and have revealed that, in agreement with the ferret 
studies described above, many disparate influenza viruses that exhibit a respiratory tropism 
in human beings are nonetheless capable of binding to and replicating in human ocular cells. 
Unfortunately, as these studies have largely been done with cultured monolayers or ex-vivo 
tissues, they are not designed to capture the involvement of ocular surface mucins or tear 
film in infection dynamics. As ocular secretory mucins possess sialic acids and serve an 
important role in host defence,52,53 characterisation of the role ocular secretions play in 
preventing or facilitating influenza virus infection is necessary.
Experimental demonstration of the susceptibility of the ocular epithelial surface to influenza 
virus infection with both avian and human viruses has shed further light on poorly 
understood areas for which additional research is needed to address questions regarding 
ocular tropism independent of virus subtype. Although our understanding of the receptor-
binding profile of H7 haemagglutinins has improved in recent years,54 it is unlikely that 
ocular tropism is governed solely by this property, as binding of both human and avian 
influenza viruses to mammalian ocular tissue has been reported.43 However, when 
considering the role cellular receptors appear to play in the ocular tropism of other 
respiratory pathogens,52 a more detailed investigation regarding the distribution of glycan 
receptors on the human ocular surface, as conducted previously for human respiratory tissue,
55 is warranted. In situations where respiratory but not ocular protection is worn, the 
nasolacrimal duct plays a critical function in facilitating the drainage of virus-containing 
fluid from the eye to the nasopharyngeal space, but does not represent a frequently studied 
tissue in influenza research, nor has the ability of influenza virus to replicate specifically 
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within this tissue (found to possess both α2,3 and α2,6 linked sialic acid) been shown 
experimentally.56 The dynamics of tear fluid exchange, from eye to nose but also from nose 
to eye, is similarly understudied in the context of viral infection, but nonetheless warrants 
investigation,53 as intranasally administered solutions can be detected at the conjunctival 
mucosal surface and infectious virus has been detected in ocular samples (conjunctival 
washes and whole eye tissue) of ferrets inoculated intranasally.43,57 Continued research in 
these areas is needed to more fully elucidate how influenza viruses reach the corneal and 
conjunctival epithelia and spread to the nasopharyngeal space. This is of special importance, 
as the eye mucosa shares several immunological features with other mucosal compartments, 
and as such, the use of eyedrop vaccination against influenza virus is under investigation as 
an alternative vaccine strategy capable of inducing protective immunity.58,59
H7 viruses represent a critical tool for unlocking ocular tropism
Due to their breadth of mammalian virulence, varied tropism, and establishment of lineages 
on multiple continents, H7 subtype viruses exhibit a wide and often underappreciated 
heterogeneity compared with other avian influenza virus subtypes associated with human 
infection, representing a challenge for their study. H7 outbreaks in poultry have been 
reported throughout North America, Europe, and Asia (figure); depopulation activities 
related to containment of these epornitics (ie, outbreaks in avian populations) can lead to 
occupational exposure of workers, as numerous human cases with A H7N3 and A H7N7 
viruses have resulted concurrent with this work (table 1).15,16,20 Continued surveillance of 
H7 viruses is needed in both wild bird and gallinaceous poultry populations to assess the 
generation of HPAI viruses from LPAI precursors and the associated potential exposure risk 
posed to human beings with these viruses.60
Avian influenza viruses, notably H5 and H7 subtype viruses associated with human 
infection, have been found to be poorly immunogenic in mammals,61 leading to difficulties 
in identifying mild or asymptomatic cases. Although supportive evidence is lacking, it is 
possible, in conjunction with a poorly immunogenic H7 haemagglutinin that infection 
stemming from ocular exposure, or disease when ocular and not respiratory symptoms are 
the primary indicator of disease, contributes to this decreased immune activation or 
depressed serological responses to infection, or both.62 Retrospective studies from H7 
outbreaks have identified many individuals with evidence of seroconversion to H7 virus 
using modified, untraditional assay conditions (in the absence of detectable neutralising 
antibody titres).63 Furthermore, individuals with positive PCR tests for influenza H7 have 
been identified in the absence of diagnostic seroconversion.64 Just as increased efforts to 
identify immune correlates of protection are needed, continued investigation to understand 
differences in the magnitude of induction of host responses following ocular exposure or 
ocular disease is required to best identify all potentially exposed individuals. Additional 
studies in this area will greatly facilitate our understanding of these properties.
Research regarding the ocular tropism associated with H7 viruses has focused primarily on 
the contribution of surface glycoproteins, and rightfully so, as one study identified that the 
combination of haemagglutinin and neuraminidase genes was necessary to maintain the 
conjunctival tropism of a 2009 A H1N1 virus in vitro.50 That said, the presence of an H7 
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haemagglutinin was found to most strongly affect the frequency of murine infection with 
influenza virus following ocular inoculation, suggesting that the neuraminidase with which 
the H7 haemagglutinin was paired or the lineage from which the neuraminidase was derived 
were less crucial for this property.46 It is likely that the H7 haemagglutinin possesses unique 
features compared with other virus subtypes; for example, it appears that differential 
molecular mechanisms confer an HPAI phenotype in H5 viruses (acquisition of multiple 
basic aminoacids at the haemagglutinin cleavage site) versus H7 viruses (both multiple basic 
aminoacid acquisition and non-homologous recombination with other viral proteins or host 
rRNA).20,65 Further identification of subtype-specific properties of the haemagglutinin are 
needed to better explain these functional differences. Beyond surface glycoproteins, there is 
growing evidence that internal proteins might play a role in H7 subtype-specific immune 
activation66 and ocular tropism.46 Unlike HPAI A H5N1 viruses, which frequently elicit 
heightened induction of proinflammatory mediators, HPAI H7 subtype viruses often elicit 
delayed and weakened responses in laboratory assays.61,67 As such, identification of 
differential induction of host signalling pathways between influenza viruses associated with 
respiratory disease compared with influenza viruses associated primarily with human 
conjunctivitis points to potential roles in host responses governing tissue tropism.47,66
It is likely that, like virus transmissibility, ocular tropism is a polygenic trait. Although 
several properties have been observed more frequently among ocular-tropic compared with 
respiratory-tropic influenza viruses (such as the presence of an H7 haemagglutinin and 
maintenance of an avian α2,3 receptor binding preference), these features appear neither 
necessary nor sufficient for a virus to bind to, replicate in, or spread from the eye to 
susceptible respiratory tissue. In this regard, the unanswered question of what separates the 
respiratory tropism evident following human infection with LPAI and HPAI A H7N9 viruses 
and the ocular disease associated with the majority of other H7 subtype viruses in human 
beings offers an opportunity to examine in more detail the molecular correlates of ocular 
tropism. With more than 1600 confirmed cases and a greater than 30% fatality rate since 
their first detection in human beings in 2013, the pandemic threat posed by A H7N9 viruses 
is evident.23 Research is ongoing to elucidate what features differentiate the severe 
respiratory disease associated with A H7N9 and A H5N1 human infection,68 but further 
efforts should similarly be made to better understand the respiratory tropism associated with 
this ongoing outbreak. Thus, although non-H7N9 H7 subtype viruses are not as frequently 
studied in the laboratory as A H7N9 or A H5N1 viruses, greater inclusion of ocular-tropic 
H7 viruses in influenza virus research will facilitate identification of what molecular 
determinants govern virus tropism, in both ocular and respiratory tissues.
Conclusions
Laboratory data show that a diverse range of human and avian influenza viruses are capable 
of replicating in several discrete ocular cell types in vitro, and can effectively use ocular 
exposure to mount a productive respiratory infection in vivo. It is reasonable to assume 
similar occupational exposure during culling and depopulation activities necessitated by 
either H5 or H7 infection in poultry, yet reports of ocular complications predominate among 
workers exposed to H7 subtype viruses only, indicating that not all virus subtypes appear to 
equally exploit this entry route in human beings. Thus, there remains a need to distinguish 
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what is possible among all viruses (as we demonstrate in the laboratory) from what is unique 
to H7 subtype viruses (as is supported by epidemiological data). Only then will we 
understand the properties that confer an ocular tropism to select groups of influenza viruses 
in human beings.
Only a fraction of all human infections with influenza viruses present with ocular 
complications. Although routes of influenza virus transmission between human beings are 
varied,69 it is assumed that exposure of respiratory tract tissue, and not ocular tissue, to 
aerosolised influenza virus represents a dominant mode. Protecting the ocular mucosal 
surface prevents influenza virus from potentially exploiting a mucosal surface with an 
anatomical conduit to the nasopharynx and respiratory tract. Use of eye protection is 
recommended in some circumstances where there is risk of influenza virus infection.70–73 
Continued investigation of the capacity for respiratory viruses to gain entry to the respiratory 
tract and to cause ocular complications will improve understanding of how these pathogens 
cause human disease, regardless of the virus subtype or exposure route.
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Figure. Detection of H7 subtype influenza viruses in avian species
Outbreaks of H7 subtype highly pathogenic avian influenza (HPAI) and low pathogenic 
avian influenza (LPAI) in avian species reported to the World Animal Health Information 
Database and the World Organization for Animal Health since 2005 and 2006, respectively; 
detailed outbreak reports can be located from these sources. Neuraminidase subtype paired 
with H7 haemagglutinin is shown. Norway, Portugal, Vietnam, and France reported 
presumed or confirmed H7 subtype outbreaks of low avian pathogenicity in the absence of 
neuraminidase determination.
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Table 2
Documented ocular complications concurrent with non-H7 influenza virus infection in human beings by 
subtype
Population Clinical presentation Demographic Proportion*




A H1N1 pdm0927 Laboratory-confirmed cases in the USA Conjunctivitis Pregnant women
Non-pregnant people
  3/34 (9%)
81/730 (11%)
A H1N1 pdm0928 Hospitalised cases in the USA Conjunctivitis Children
Adults
  1/86 (1%)
4/169 (2%)
A H1N1 pdm0929 Hospitalised children, South Korea Conjunctivitis Children   6/777 (0·8%)
A H1N1 pdm0930 Laboratory-confirmed cases, Cyprus Conjunctivitis Children   3/45 (7%)
A H1N1 pdm0931 Military cadets with confirmed infection Conjunctivitis Young adults (17–24 
years)
  6/86 (7%)
A H1N1 pdm0932 Laboratory-confirmed cases, Egypt Conjunctivitis Not specified 58/89 (65%): 81% 
of which were 
bilateral
seasonal A H1N1, 
A H3N2, B33
Military personnel with febrile respiratory 
illness, Singapore
Sore eyes/eye pain Adults >30% among 821
A H3N2 variant24 Laboratory-confirmed cases in the USA, 
2012
Eye irritation/redness Not specified 57/243 (23%)
A H5N134 Hospitalised cases in Egypt, 2006–07 Conjunctivitis Not specified 14/38 (37%)
A H5N135 Hospitalised cases in Turkey, 2006 Conjunctivitis Children (5–15 years)   1/8 (12·5%)
A H10N736 Poultry abattoir workers in Australia, 2010 Conjunctivitis Adults   2/2 (100%)†
*
Number of cases presenting with ocular complications as described among all individuals with confirmed influenza virus infection.
†
Nine additional abattoir workers and farm staff members showed signs of conjunctivitis but influenza virus infection was not confirmed by RT-
PCR.
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Table 3
Frequency of reported ocular complications (conjunctivitis or pink eye) reported within 2 weeks of hospital 
admittance with a positive influenza test, Influenza Hospitalization Surveillance Network (FluSurv-NET*), 
2014–15 to 2015–17
2014–15 2015–16 2016–17
Patients with conjunctivitis† 80 (0·45%)† 57 (0·65%)† 118 (0·70%)†
Age group, years
 0–4 22 (27·5%) 30 (52·63%) 13 (11·02%)
 5–17 11 (13·75%) 13 (22·81%) 11 (9·32%)
 18–49   8 (10%)   3 (5·26%) 16 (13·56%)
 50–64   7 (8·75%)   7 (12·28%) 22 (18·64%)
 65+ 32 (40%)   4 (7·02%) 56 (47·46%)
Influenza type
 A 64 (80%) 44 (77·19%) 91 (77·12%)
 B 15 (18·75%) 12 (21·05%) 25 (21·19%)
 A/B   1 (1·25%)   1 (1·75%)   2 (1·69%)
A subtype‡
 H3N2 28 (43·75%)   3 (6·82%) 58 (63·04%)
 H1N1 pdm09   0 19 (43·18%)   1 (1·09%)
 Unknown 36 (56·25%) 22 (50·00%) 33 (35·87%)




Percentage of patients with conjunctivitis out of all respondents, n=17 623 (2014–15), n=8780 (2015–16), and n=16 885 (2016–17). Samples 
represent any influenza virus-positive clinical isolate; ocular samples were not uniformly tested.
‡
In 2016–17, one case with influenza type “A/B” was subtyped and is thus counted twice in the table.
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Table 4
Permissiveness of influenza A virus infection following ocular exposure in ferrets, by subtype
Liquid ocular inoculation* Aerosol ocular-only inoculation†
Virus Inf‡ Virus Inf‡
HPAI A H7N7 A/Netherlands/219/03 3/3 A/Netherlands/219/03 3/3
HPAI A H7N3 A/Canada/504/04 2/3 A/Mexico/7218/12 3/3
LPAI A H7 A/NY/107/03 (H7N2) 3/3 A/Shanghai/1/13 (H7N9) 3/3
HPAI A H5N1 A/Thailand/16/04 3/3 A/Thailand/16/04 3/3
A H1N1 A/Brisbane/59/07 3/3 A/Brisbane/59/07 3/3
A H1N1 pdm09 A/Mexico/4108/09 3/3 A/Mexico/4482/09 3/3
A H3N2 A/Panama/2007/99 (seasonal) 3/3 A/Indiana/8/11 (variant) 3/3
*
100 μL of diluted virus deposited onto the surface of the right eye of a sedated ferret. Experimental data previously published.42
†
Passage of aerosolised virus through close-fitting goggles worn by a sedated ferret in the absence of respiratory exposure. Experimental data 
previously published.40,42
‡
Number of infected ferrets/total number of inoculated ferrets, as determined by the presence of infectious virus in nasal wash specimens collected 
days 1–7 post inoculation.
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